Abstract
Background
Placenta previa and placenta accreta spectrum (PAS) are characterized by irregular placental implantation and invasion, which can lead to significant maternal and fetal morbidity. Survivin is a critical protein that affects cellular longevity and apoptosis, and plays a crucial role in placental development during pregnancy. This study aimed to examine the maternal serum survivin levels in patients with normal placentation, placenta previa, and PAS.
Methods
In this prospective cross-sectional study, we enrolled 84 pregnant women categorized into the control (n=42), placenta previa (n=24), and PAS (n=28) groups. Serum survivin levels were quantitatively determined using ELISA.
Results
A significant elevation in serum survivin levels was observed in the placenta previa and PAS groups compared to the controls, suggesting a role for survivin in the pathophysiological response to against abnormal placental adherence and invasion.
Conclusions
Elevated serum survivin level may serve as an early biomarker for diagnosing and managing placenta previa and PAS, underscoring the need for a multidisciplinary approach to managing these complex pregnancy complications.